Healthcare / BiotechnologyStockholm
$3.66
+0.14 (+3.98%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $-11.7M · quality 41.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
22/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$76M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-40.4%
↓Gross Margin
82.2%
↑Debt/Equity
0.87
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+24.8%
FCF CAGR
—
FCF margin
-11.3%
FCF / Net income
0.20x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $282.9M · net income $-159.9M · FCF $-31.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $282.9M | $282.9M | $236.0M | $170.4M | $145.7M |
| Net Income | $-159.9M | $-159.9M | $11.9M | $12.2M | $9.1M |
| EBITDA | $-24.3M | $-24.3M | $59.2M | $31.4M | $25.8M |
| EPS | -7.74 | -7.74 | 0.93 | 1.13 | 0.85 |
| Gross Margin | 82.2% | 82.2% | 93.9% | 90.3% | 92.2% |
| Operating Margin | -48.1% | -48.1% | 3.2% | 10.8% | 10.2% |
| Net Margin | -56.5% | -56.5% | 5.1% | 7.1% | 6.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.87 | 0.87 | 0.62 | 0.38 | 0.34 |
| Current Ratio | 1.37 | 1.37 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-31.9M | $-31.9M | $-11.7M | $209000.00 | $-4.4M |
| Returns | |||||
| ROE | -40.4% | -40.4% | 2.1% | 7.7% | 6.2% |
| Valuation | |||||
| P/E | — | — | 39.57 | 22.30 | 31.65 |
| EV/EBITDA | — | — | 18.61 | 10.34 | 12.80 |
| P/B | 0.19 | 0.19 | 1.35 | 1.72 | 1.97 |
| Growth & Yield | |||||
| Revenue Growth | 19.9% | 19.9% | 38.5% | 17.0% | — |
| EPS Growth | -932.3% | -932.3% | -17.7% | 33.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-87.3%
Start / end P/E
n/dx → n/dx
EPS bridge
0.93 → -7.74
Residual
-87.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.